Selecta Biosciences to Participate in Upcoming Investor Conferences
08. September 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank
01. September 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
06. August 2020 07:30 ET
|
Selecta Biosciences, Inc.
Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research...
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer
03. August 2020 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Participate in Upcoming Investor Conferences
03. August 2020 08:15 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights
30. Juli 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
28. Juli 2020 06:00 ET
|
Selecta Biosciences, Inc.
STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta...
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
18. Juni 2020 08:30 ET
|
Selecta Biosciences, Inc.
CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences,...
Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference
15. Juni 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
11. Juni 2020 17:15 ET
|
Selecta Biosciences, Inc.
- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need...